Equilenin is one of ten kinds of estrogens that are found in pregnant mares' urine. It has been used extensively for estrogen replacement therapy in postmenopausal women. Typical inducers of the cytochrome P4501A1 (CYP1A1), such as TCDD, benzo(a)pyrene (B(a)P) and 3-methylcholanthrene, have a planar molecular structure in common and bind to the aryl hydrocarbon receptor (AhR). The structure of equilenin differs from classic estrogens by the presence of two additional double bonds in ring B of the steroid nucleus, and it is planar. This structural similarity of equilenin to the typical AhR agonist prompted us to investigate the capability of equilenin to induce CYP1A1 expression. Administration of equilenin to two mouse strains (C57BL and DBA) that exhibit different degrees of responsiveness to an Ah-receptor agonist and showed that equilenin was capable of dose-dependently increasing both the ethoxyresorufin-O-deethylase activity and CYP1a proteins in both strains of mice.
Introduction
Equilenin belongs to the equine estrogen family, which is composed of 10 different estrogens produced only during pregnancy, and is excreted in the urine of pregnant mares [1] . Equilenin binds to the estrogen receptor and exhibits estrogenic action, the potency of which is comparable to, if not exceeding, that of 17B-estradiol. Therefore, a preparation of the conjugated form of equilenin (Premarin), which is purified from the urine of pregnant mares, has been successfully used in the hormone-replacement therapy of postmenopausal symptoms.
Estrone and 17β-estradiol are estrogens that have a saturated B-ring, and are biosynthesized from cholesterol through a classic steroid synthetic pathway. Equilenin, which has a partially planar structure with aromatic A and B rings (Figure 1 ), is biosynthesized through a different pathway [2] from that of estrone and 17β-estradiol.
It was this planar structure that prompted us to think that equilenin may be a ligand to the arylhydrocarbon receptor (AhR) and might induce members of the CYP1 family. Induction of the CYP1 family is triggered by the activation of AhR by a group of organochlorides, such as co-planar polychlorinated biphenyls (PCBs) and polychlorinated dibenzo dioxins (PCDDs), and planar polycyclic aromatic hydrocarbons (PAHs), such as benzo(a)pyrene (B(a)P), 3-methylcholanthrene (3-MC), β-naphthoflavone and others. A group of lipophilic azo-naphthol compounds, such as 1-phenylazo 2-naphthol, with a structure capable of forming planar 3 fused 6-membered rings by the formation of intra-molecular hydrogen bonds can also be AhR ligands [3, 4] . As has been pointed out by this work and others [5, 6 ], planarity appears to be an important requirement for AhR ligands. Interestingly, a comparison of the chemical structures of these known AhR ligands with that of equilenin shows that the molecular structure of this planar estrogen can be almost perfectly superimposed on that of 3-MC ( Figure 1 ). In this study, we found that this estrogen -3 -indeed binds to AhR and induces CYP1A subfamily members. This is the first reported AhR ligand that is known to be biosynthesized endogenously.
Materials and Methods

Chemicals and reagents
All the test substances and reagents used were of reagent grade including those described below. Equilenin, benzo(a)pyrene (B(a)P), resorufin, ethoxyresorufin, dimethyl sulfoxide (DMSO), dithiothreitol (DTT), phenylmethylsulfonyl fluoride (PMSF), aprotinin, Triton X-100 and dextran-coated charcoal were purchased from Sigma, USA. HEPES, ethylenediaminetetraacetic acid (EDTA) was from Dojindo Laboratories, Japan; NADPH, glucose-6-phosphate (G-6-P) and glucose-6-phosphate dehydrogenase (G-6-PDH) was from Oriental Yeast, Japan; [ 3 H]B(a)P (76.0 Ci/mmol) was from Amersham Pharmacia Biotech, UK. All other reagents were analytical grade or the highest quality available and purchased from Wako Pure Chemical Industries, Japan.
Animals
C57BL mice (SLC, Japan) obtained at the age of 6 weeks were used in the experiments after acclimatization for 1 week. 1 mg/kg or 20 mg/kg solution of equilenin, or 20 mg/kg of B(a)P in corn oil was administered intraperitoneally to each group (three 7-week-old mice) repeatedly over a period of 3 days. Corn oil was administered to the control animals at the same dose volume (10 ml/kg). Twenty-four hr after the final administration, the mice were killed by decapitation under light anesthesia with CO 2 .
The liver was excised immediately from each mouse, and perfused with an ice-cold 1.15% KCl solution to remove the blood.
Microsomes were prepared by the method of Omura and Sato [7] . The protein concentration was determined by the method of Lowry et al. [8] .
Assay of ethoxyresorufin O-deethylation (EROD) activity
The activity of ethoxyresorufin O-deethylation was determined by the method of Burke et al. [9] with slight modification. One ml of the reaction mixture containing an appropriate concentration of microsomal protein, 10 mM G-6-P, 10 mM MgCl 2 and 20 µM ethoxyresorufin in 20 mM Tris-HCl (pH 7.8) was preincubated for 5 min at 37ºC. The reaction was started by adding 20 µl of a mixture of 50 mM NADPH and 200 U/ml of G-6-PDH. After incubation for 5 min, the reaction was terminated by adding 4 ml of cold methanol. The mixture was centrifuged at 3000 rpm for 5 min, and the supernatant methanol layer was collected for measurement of resorufin. Resorufin was measured using a fluorescence spectrophotometer (FP777, JASCO). The excitation wavelength was set at 528 nm and the emission wavelength at 590 nm.
Western blot analysis
Polyacrylamide gel electrophoresis (SDS-PAGE) was conducted according to the method of Laemmli [10] , using 10% polyacrylamide and 15 µg microsomal protein. After electrophoresis, the proteins in the gel were transferred to a PVDF membrane by an electrophoretic transfer method. The antigen-antibody reactions were carried out after blocking of the -4 -membrane with 5% skimmed milk solution using a goat anti-rat CYP1A1 serum (diluted 1:500, Daiichi Pure Chemicals, Japan)
as the first antibody and a rabbit anti-goat IgG antibody conjugated with peroxidase ( removed from the surface of the culture flask. The cells were collected and centrifuged at 110×g for 3 min to remove the supernatant solution. The cell pellet was appropriately suspended in the buffer, diluted and inoculated to a new culture flask.
Assay of CYP1A1 mRNA induced by equilenin
HepG2 cells were plated on a 6-well plate at a cell density of 1. A 50 µl aliquot of the Taqman Universal PCR Master Mix containing an appropriate amount of the template cDNA, 3 µM of primers and 2 µM of Taqman probe was prepared, and real-time PCR was performed by 50 cycles of incubation at 95ºC for 15 sec, followed by incubation at 60ºC for 1 min. The PCR product was subcloned into a pCR2.1 vector (Invitrogen, USA) to prepare the standard curve.
Luciferase assay
The promoter sequence of human CYP1A1, which was integrated into a pRNH241c vector provided by Dr. Piechocki and Dr.
Hines (Department of Pharmacology, Wayne State University School of Medicine, USA) [12] , was inserted to an enhancer region of a PGL3 Reporter Vector (Promega, USA) coding a luciferase gene of the firefly. For correction of transfection efficiency, the HepG2 cells were transfected simultaneously with pPL Control Vector (Promega) coding Renilla luciferase. The transfection was performed using Lipofect AMINE PLUS (GIBCO BRL) according to the manufacturer's instruction manual. A serum-free medium was used for transfection, and was replaced with medium containing serum 3 hr after the transfection. The cells were treated 12 hr after the medium change with DMSO (0.1%) as a control and equilenin or B(a)P at final concentrations of 1, 10 and 30 μM and 0.1, 0.5 and 1 μM, respectively, for 24 hr. The activity of luciferase was measured 24 hr after addition of the test substances. The assay of luciferase was performed using a Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer's instruction manual. The chemiluminescence was measured using a Luminescencer JNR (ATTO, Japan). The measurement was conducted continuously for 2 min after addition of luminescent substrate, and the integrated value for 2 min was used. The AhR expression vector (10 µg/150 mm dish) was transfected into 293T cells using Lipofect AMINE PLUS (GIBCO BRL)
Expression of fusion protein of recombinant
according to the manufacturer's instruction manual. A serum-free medium was used in transfection and was replaced with a serum-containing medium at 3 hr after the transfection. Seventy-two hr after starting the transfection, the cells were washed with D-PBS twice, detached from the flask with a cell scraper and collected by centrifugation at 3000 rpm for 5 min at 4ºC. The collected cells were re-suspended in HBS buffer (10 mM HEPES, 0.15 M NaCl, 1 mM DTT, 0.01% TritonX-100, 1 mM PMSF and 1 µg/ml aprotinin, pH 7.5) and homogenized by sonication for 30 sec. The cell homogenate was centrifuged at 10,000×g for 30 min at 4ºC, and the supernatant fraction was collected.
The recombinant fusion protein of AhR with a His-tag in the cell extract was purified using a HisTrap Kit (Amersham Pharmacia Biotech). According to the manufacturer's instruction manual, a solution of Ni 2+ was applied to a 1 ml HiTrap Chelating HP column, which was then washed with ultra-pure water. After washing, the column was equilibrated with 10 ml of a starting buffer (phosphate buffer, 10 mM imidazole). The cell extract was filtered through a membrane filter (0.45 µM), combined with imidazole at a final concentration of 10 mM and applied to the equilibrated column. Proteins were eluted with 5 ml of an elution buffer (phosphate buffer, 500 mM imidazole). The eluate was collected in fractions of 0.5 ml each. The flow rate of the buffer was set at 1 ml/min and all the procedures were performed at 4ºC. The protein concentrations in the fractions were determined, and three fractions containing a high concentration of protein were identified (1.5 ml). Western blot analysis of the fractions was also conducted using anti mouse AhR (Novus Biologicals, Inc., USA) to detect the expressed protein with a size of about 93 kDa.
The fractions containing high protein concentrations (1.5 ml) was applied to a HiTrap Desalting column (Amersham Pharmacia Biotech) to remove the salt and exchange the buffer. The column was equilibrated with an elution buffer (25 mM HEPES, 1.5 mM EDTA, 1 mM DTT, pH 7.4) at a volume not less than 15 ml. After application of the sample, the elution buffer was passed through the column by a pump at a flow rate of 2.5 ml/min, and the eluate was collected in 5 fractions of 1 ml each. All the procedures were performed at 4ºC. The protein concentration in each fractions was determined to identify the fractions containing the protein. The fractions were frozen in liquid nitrogen and stored at -80ºC until use.
Assay of equilenin binding to C57BL AhR
A 200 µl aliquot of the desalted fraction of AhR (100 µg protein/ml) was incubated with 10 nM 
Statistical analysis
Statistical analyses were performed by ANOVA and post hoc tests (Fisher's PLSD and Scheffe's test). The values were expressed as the mean value ± standard error, and the difference at a level of significance less than 0.05 (P < 0.05) was regarded as statistically significant. (Figure 2A ). Western blot analysis using rat CYP1A1 antibody revealed increased expression of CYP1A protein in liver microsomes of mice ( Figure 2B, 2C) . The potency of the induction by equilenin was slightly more than a half of that by B(a)P at the same dose.
Results
Induction
Induction of CYP1A by equilenin in HepG2 cells
The effect of treatments with 1, 3, 10 and 30 μM equilenin on the HepG2 cells was investigated. HepG2 cells have endogenous AhR. Assay for CYP1A1 mRNA in equilenin-treated HepG2 cells was conducted using a Taqman probe and primer set that is specific to human CYP1A1 mRNA. The induction of mRNA by equilenin was concentration-dependent, and at a concentration of 30 µM of equilenin, about 15-fold induction was observed (Figure 3 ).
Effect of equilenin on activation of transcription via XRE
In order to investigate the mechanism of CYP1A induction observed in C57BL mice and in HepG2 cells, a luciferase reporter assay system was constructed by transiently transfecting HepG2 cells with the CYP1A1 5' flanking reporter plasmids, pGL3-XRE, together with the pGL-TK control plasmid (Materials and Methods), and transcriptional activation by XRE after addition of equilenin was investigated using this assay system. Equilenin at concentrations of 1, 10 and 30 µM showed the activation of transcription equivalent to the levels of activation by B(a)P at concentrations of 0.1, 0.5 and 1 µM (Figure 4 ), indicating that the potency of equilenin is about one tenth to one thirtieth of that of B(a)P.
Affinity of equilenin to AhR
AhR protein of C57BL mice was prepared as described in Materials and Methods. Affinity of equilenin to C57BL AhR was evaluated by a competition assay using radiolabeled B(a)P, an archetypal ligand of AhR. The results obtained were compared with those obtained with 3-MC. 3-MC at concentrations of 0.1 -10 nM showed concentration-dependent inhibition of the binding of 10 nM [ 3 H]B(a)P with AhR, and the inhibition was almost 100% at a concentration of 10 nM. Equilenin at a concentration of 10 μM caused 25% inhibition and at 300 µM, about 50% inhibition ( Figure 5 ). Although equilenin was found to be a far weaker ligand to AhR than 3-MC, the results nevertheless indicate that it binds to AhR.
Discussion
The arylhydrocarbon receptor is a transcriptional factor that has a bHLH (basic-helix-loop-helix)-PAS (Per/ARNT/Sim) structure and forms a complex with two molecules of 90 kDa-heat shock protein (HSP90) in the cytosol. AhR binds exogenous ligands such as PAHs, PCBs and PCDDs in the cytosol, then migrates into the nucleus and forms a heterodimer with the arylhydrocarbon receptor nuclear translocator (ARNT) after dissociation from HSP90. This heterodimer was demonstrated to activate gene transcription by binding to a xenobiotic responsive element (XRE) that has a 5'-GCGTG-3' DNA sequence as a core motif, and which is present in the regulatory region of a number of target genes such as CYP1A1 [14] , CYP1A2, CYP1B1, NAD(P)H-quinone oxidoreductase (NQO)-1, the Ya subunit of glutathione-S-transferase (GST), UDP-glucuronosyl transferase (UGT1) and aldehyde dehydrogenase (ALDH)-3.
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By investigating the structure-activity relationship of the ability of 40 azo-compounds to induce CYP1A1, Fujita et al. [3, 4] concluded that lipophilic azo-naphthol compounds, such as 1-phenylazo-2-naphthol, capable of forming coplanar 3 fused The compounds with a benzoimidazole structure, typically omeprazole, have been known to induce CYP1A1 in cultured human cells [16] . Kikuchi et al. showed that the induction of CYP1A1 by omeprazole was not inhibited by α-naphthoflavone, an AhR antagonist, but the induction was inhibited by tyrosine kinase inhibitors, demonstrating that the signal transduction system mediated by a ligand-independent tyrosine kinase is involved in the induction [17] . On the contrary, Dzeletovic et al.
demonstrated that the ligand binding site of AhR is related to the reactivity to omeprazole [18] , suggesting a possibility of sulfenamide generated by acid decomposition of omeprazole with a very short half-life being produced and bound to AhR.
Omeprazole has a planar benzimidazole structure. The possible addition of the third ring fused to the two-ring structure by intramolecular hydrogen bonding between NH of imidazole and sulfoxide oxygen may also fulfill the structural requirement for an AhR ligand as in the case of 1-phenylazo-2-naphthol.
Substances such as omeprazole, primaquine [19] and carbaryl [20] are classified as atypical CYP1A1 inducers; several mechanisms of induction have been proposed for them [21] [22] [23] [24] . All of these inducers, however, have planar structures of two fused rings, and if those rings are joined by another ring formed by the intramolecular hydrogen bonding either before, if possible, or after hydroxylation of the ring by metabolism, they might be able to bind to AhR. It is then hypothesized that these compounds or metabolites, which are capable of forming additional rings, fuse to two coplanar ring structures by intramolecular hydrogen bonding to induce CYP1A1 by acquiring the ability to bind to AhR. The hydroxylation of these compounds would be possible in vivo, but in an AhR binding assay without a drug-metabolizing mechanism, these compounds would not be hydroxylated and unable to form intramolecular hydrogen bonding and therefore, may not successfully compete for the binding or be a very weak ligand. In fact, Denison et al. showed that carbaryl was a very weak AhR ligand by using a low nonsaturating concentration of radiolabeled TCDD in the ligand-binding assay [5, 22] .
A recent study [25] indicated that 1 mM primaquine successfully displaced 5 nM tritium-labeled TCDD from AhR, while 3 mM omeprazole failed to displace it. These authors suggested that high-and low-affinity ligands for the AhR interact with different residues of the AhR ligand-binding pocket.
Induction of Cyp1a was observed after administration of equilenin to C57BL mice (Figure 2 ). Focusing attention on the fact that equilenin has a planar structure similar to 3-MC, a known AhR ligand, it is highly likely that equilenin binds to AhR and, therefore, induces CYP1A in mice via the AhR-mediated mechanism. In order to confirm this possibility, we first investigated the effect of equilenin on HepG2 cells, a cell line that has been frequently used as the hepatic model, to confirm that the observed increase in CYP protein level is indeed an induction involving a transcriptional process. In the assay of mRNA using a probe and primer set specific to human CYP1A1 mRNA, a significant increase in mRNA level was observed after treatment of HepG2 cells with equilenin at a concentration of 30 µM.
To investigate the involvement of AhR in the induction of CYP1A by equilenin, a binding assay using expressed AhR was conducted. We transfected C57BL-AhR expression vector (pCAGGS) with His-tag sequence into 293T cell, and AhR in cytosolic fraction was purified using anti-His-tag antibody. AhR possessed affinities to the AhR ligands, B(a)P and 3-MC, and
we did not re-add any co-factor proteins, such as HSP90, after the purification step. In the binding assay using Previous studies on estrogens with an unsaturated B-ring have been focused on its risk of carcinogenesis. It has been reported that 17β-dihydroequilenin is hydroxylated at the 4-position by CYP1A1 and CYP1B1, and autoxidized to a quinone form, which causes the DNA injury [26] . Therefore, induction of CYP1A1 may increase this risk. This DNA-damaging action by 17B-dihydroequilenin is known to be higher than that of 4-hydroxy estrone, the endogenous hormone, in the cells having estrogen receptors [27] . 17β-Estradiol is known to undergo hydroxylation at the 2-position by CYP1A1/2 [28, 29] and at the 4-position by CYP1B1 [30] . The difference in the CYP isoforms responsible for hydroxylation is probably due to the B-ring of these estrogens being aromatic. According to the results of previous studies [31, 32] in Syrian hamsters, a mixture of Premarin hydroxylates, equilenin and equilin, caused tumorigenesis at a rate of 100% while the rate of tumorigenesis was 75% and 0% after treatment with either equilin or equilenin, respectively. The metabolite of CYP, hydroxylated equilenin, has been considered to be involved in the tumorigenesis. Because the estrogens with the unsaturated B-ring are hydroxylated at the 4-position, it has been reported that hormone replacement therapy over a long period using Premarin is accompanied by an increased risk of carcinogenesis.
Induction of drug-metabolizing enzymes via AhR in response to xenobiotic compounds is regarded as a rational response to achieve the purpose of metabolizing and excreting the ligand xenobiotics. There were physiological studies using AhR-knockout mice [33] [34] [35] [36] , however, the role of AhR has not been clarified in detail yet. Although several compounds have been proposed as candidates for endogenous AhR ligands [37, 38] , none of them has been identified as a biosynthesized endogenous ligand to date, and AhR is still classified as the orphan receptor. We have shown that equilenin, an endogenous steroid hormone, served as the AhR ligand in the present study. We do not think that equilenin can be generalized as the physiological AhR ligand because it is not found in animals other than pregnant mares. However, we believe that the results obtained here are very important in understanding the role of the AhR and give incites into the further study. 
